Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines. 1995

J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
International Centre for Diarrheoal Disease Research, Bangladesh, Dhaka.

In a field trial carried out in 1985 in Matlab, Bangladesh, the authors evaluated whether subjects who developed Vibrio cholerae 01 infections during the first year after earlier receipt of B subunit-killed whole cell (BS-WC) or killed whole cell-only (WC) oral cholera vaccines exhibited deficient serum vibriocidal immune responses to these infections. After severe V. cholerae 01 infections (n = 70) in subjects > 5 years of age, the age group in which both vaccines were efficacious, a 6.5 geometric mean-fold rise of serum vibriocidal antibodies was observed among vaccinees, compared with an 18.6 geometric mean-fold rise in placebo-recipients (p < 0.01). Depressions of serum vibriocidal responses among vaccinees were even more marked after asymptomatic infections (n = 30): a 1.1 geometric mean-fold rise in vaccinees versus a 5.9 geometric mean-fold rise in placebo-recipients (p < 0.01). The authors conclude that subjects who failed to be protected by BS-WC and WC, despite being in the age group for which these vaccines were protective, exhibited poor immune responses even to the vigorous stimulus of natural infection. These findings raise the possibility that immune hyporesponsiveness may limit the potential efficacy attainable by cholera vaccines in populations with endemic cholera.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002771 Cholera An acute diarrheal disease endemic in India and Southeast Asia whose causative agent is VIBRIO CHOLERAE. This condition can lead to severe dehydration in a matter of hours unless quickly treated. Vibrio cholerae Infection,Choleras,Infection, Vibrio cholerae,Infections, Vibrio cholerae,Vibrio cholerae Infections
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
August 1991, The Journal of infectious diseases,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
April 2001, The Journal of infectious diseases,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
January 2024, The Cochrane database of systematic reviews,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
June 2013, Clinical and vaccine immunology : CVI,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
September 1988, The Southeast Asian journal of tropical medicine and public health,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
July 1986, Lancet (London, England),
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
April 1997, Lancet (London, England),
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
January 1995, Advances in experimental medicine and biology,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
May 2012, Clinical and vaccine immunology : CVI,
J Clemens, and M Rao, and D Sack, and F Ahmed, and M R Khan, and J Chakraborty, and B Kay, and S Huda, and M Yunus, and F van Loon
June 1973, Bulletin of the World Health Organization,
Copied contents to your clipboard!